BLTP3B: A Potential Drug Target and Biomarker (G23074)

Target Name: BLTP3B

NCBI ID: G23074

BLTP3B

BLTP3B: A Potential Drug Target and Biomarker

BLTP3B (Bridge-like lipid transfer protein family member 3B) is a protein that has been identified as a potential drug target and biomarker. The BLTP3B gene has been shown to play a role in a variety of biological processes, including the transport of lipids across cell membranes and the regulation of cellular signaling pathways.

The BLTP3B protein is a member of the bridging lipid transporter family, a family of proteins responsible for transporting various lipids in organisms. This family includes three genes, namely BLTP1, BLTP2 and BLTP3B. The proteins encoded by these genes form channels in the cell membrane through which lipids are transported from one organelle to another, or to the outside of the cell.

The function of BLTP3B in vivo has been fully studied. Research shows that BLTP3B is responsible for transporting triacylglycerol within cells, which is a key substance for intracellular energy metabolism. In addition, BLTP3B also participates in intracellular signaling pathways, such as the PI3K/Akt signaling pathway. These signaling pathways regulate various biological processes within cells, including cell proliferation, apoptosis, and cell metabolism.

Since the function of BLTP3B in vivo has been well studied, it is considered to be a potential drug target. Mutations in BLTP3B have been shown to cause various diseases, including obesity, diabetes, and cardiovascular disease. In addition, elevated BLTP3B levels have also been shown to be associated with the risk of a variety of diseases, such as hypertension and certain cancers.

In addition to its role in disease, BLTP3B is also considered a potential biomarker. By measuring the levels of BLTP3B in blood or tissue, the efficiency of intracellular triacylglycerol transport can be assessed, helping researchers understand disease development and the effectiveness of treatments. In addition, measurement of BLTP3B levels can also serve as a biomarker for certain diseases, such as diabetes, obesity, and certain cancers.

The drug target properties of BLTP3B have also been confirmed. Research shows that BLTP3B inhibitors can reduce fat storage in adipocytes and weight gain, thereby improving the treatment of obesity and diabetes. In addition, BLTP3B inhibitors can also inhibit the invasion and metastasis of tumor cells, thus providing new ideas for cancer treatment.

In short, BLTP3B is a protein with a wide range of biological functions and plays an important role both inside and outside the organism. BLTP3B mutations and levels have been shown to be associated with the risk of a variety of diseases, making it a potential drug target. In addition, BLTP3B can also serve as a potential biomarker for disease diagnosis and treatment. With the deepening of research, BLTP3B will become a research topic that attracts much attention.

Protein Name: Bridge-like Lipid Transfer Protein Family Member 3B

Functions: Tube-forming lipid transport protein which mediates the transfer of lipids between membranes at organelle contact sites (PubMed:35499567). Required for retrograde traffic of vesicle clusters in the early endocytic pathway to the Golgi complex (PubMed:35499567, PubMed:20163565)

The "BLTP3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BLTP3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets